Lipoxen signs insulin deal with Glide
This article was originally published in Scrip
Executive Summary
Lipoxen, the UK biopharmaceutical company, has signed an agreement with Glide Pharma to investigate the delivery of the long-acting insulin SuliXen for types 1 and 2 diabetes using the Glide SDI needle-free drug delivery technology.